China News Service, Beijing, March 10 (Li Yusu) During the two sessions of the National People's Congress, Lu Qingguo, a representative of the National People's Congress and chairman and general manager of Chenguang Biotechnology Group Co., Ltd., said in an interview that it is recommended to expand the scope of centralized procurement of Chinese patent medicines and include more Chinese patent medicines that are commonly used in clinical practice, used in large quantities, and have high purchase amounts are included in the national centralized procurement list. All regions are encouraged to strengthen linkage and maximize the centralized procurement of Chinese patent medicines as soon as possible.
Lu Qingguo said that in recent years, chemical drug collection has achieved remarkable results: the country has gradually advanced from the initial "4+7" pilot cities to local alliances and even inter-provincial alliances, and the coverage has continued to expand. The average price of winning drugs has been reduced by more than 50%. For solving the problem Medical treatment is expensive for the people and it has played a very good role in saving the country's medical expenses.
He mentioned that at present, various provinces are actively promoting Chinese patent medicines to enter the scope of centralized bulk procurement, and have achieved certain results. However, judging from the pilot situation, there are still some problems compared to the centralized procurement of chemical drugs. If bulk procurement is not implemented, resulting in Although some companies won the bid at a low price, they did not obtain the corresponding purchase volume, which affected the effectiveness of the policy and the enthusiasm of the winning bidders.
Lu Qingguo suggested that the centralized purchasing and volume model of traditional Chinese medicine should be standardized, and the corresponding relationship between winning bid price and purchasing volume should be clarified, so that companies that win bids at low prices can obtain sufficient purchasing volume, and encourage companies to rely on scale, innovation, and production while ensuring drug quality. Management achieves cost reduction and efficiency improvement.
In addition, Lu Qingguo suggested further optimizing the centralized procurement rules of proprietary Chinese medicines and technical evaluation and price competition scoring rules, reducing the weight of technical evaluation, fully embodying price advantages on the basis of improving pharmacopoeia standards to ensure drug quality, and maximizing drug price reduction and scientific fairness. The effect of competition.
(over)